{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:54Z","timestamp":1793973594469,"version":"4.8.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Whether stereotactic body radiotherapy (SBRT) as a bridge to liver transplant for hepatocellular carcinoma (HCC) is effective and safe is still unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the feasibility of SBRT before deceased donor liver transplant (DDLT) for previously untreated unresectable HCC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this phase 2 nonrandomized controlled trial conducted between June 1, 2015, and October 18, 2019, 32 eligible patients within UCSF (University of California, San Francisco) criteria underwent dual-tracer (18<\/jats:sup>F-fluorodeoxyglucose and 11<\/jats:sup>C-acetate [ACC]) positron emission tomography with computed tomography (PET-CT) and magnetic resonance imaging (MRI) with gadoxetate followed by SBRT of 35 to 50 Gy in 5 fractions, and the same imaging afterward while awaiting DDLT. Statistical analysis was performed on an intention-to-treat basis between October 1 and 31, 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Patients received SBRT followed by DDLT when matched deceased donor grafts were available.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Coprimary end points were progression-free survival (PFS) and objective response rates (ORRs) by the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), modified RECIST (mRECIST), and PET Response Criteria in Solid Tumors (PERCIST). Secondary end points were local control rate, overall survival (OS), and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 32 patients (median age, 59 years [IQR, 54-63 years]; 22 men [68.8%]) with 56 lesions received SBRT. After a median follow-up of 74.6 months (IQR, 40.1-102.9 months), the median PFS was 17.6 months (95% CI, 6.6-28.6 months), and the median OS was 60.5 months (95% CI, 29.7-91.2 months). The 5-year PFS was 39.9% (95% CI, 19.9%-59.9%), and the 5-year OS was 51.3% (95% CI, 31.7%-70.9%). In terms of number of patients, ORRs were 62.5% ([n\u2009=\u200920] 95% CI, 54.2%-68.7%) by RECIST 1.1, 71.9% ([n\u2009=\u200923] 95% CI, 63.7%-79.0%) by mRECIST, and 78.1% ([n\u2009=\u200925] 95% CI, 73.2%-86.7%) by PERCIST. In terms of number of lesions, ORRs were 75.0% ([n\u2009=\u200942] 95% CI, 61.6%-80.8%) by RECIST 1.1, 83.9% ([n\u2009=\u200947] 95% CI, 74.7%-90.6%) by mRECIST, and 87.5% ([n\u2009=\u200949] 95% CI, 81.3%-98.6%) by PERCIST. Twenty patients with 36 lesions received DDLT, of whom 15 patients (75.0%) with 21 lesions (58.3%) exhibited pathologic complete response. Multivariable analyses revealed that pretreatment metabolic tumor volume (MTV) based on ACC (hazard ratio [HR], 1.06 [95% CI, 1.01-1.10]; P<\/jats:italic>\u2009=\u2009.01) and complete metabolic response (CMR) by PERCIST (HR, 0.31 [95% CI, 0.10-0.96]; P<\/jats:italic>\u2009=\u2009.04) were associated with PFS, while pretreatment MTV based on ACC (HR, 1.07 [95% CI, 1.03-1.16]; P<\/jats:italic>\u2009=\u2009.01), total lesion activity based on ACC (HR, 1.01 [95% CI, 1.00-1.02]; P<\/jats:italic>\u2009=\u2009.02), and CMR by PERCIST (HR, 0.21 [95% CI, 0.07-0.73]; P<\/jats:italic>\u2009=\u2009.01) were associated with OS. Toxic effects associated with SBRT were reported for 9 patients (28.1%), with 1 grade 3 event.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This phase 2 nonrandomized controlled trial demonstrated promising survival and safety outcomes of SBRT before DDLT for unresectable HCC. Future randomized clinical trials are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.15998","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:11:03Z","timestamp":1718032263000},"page":"e2415998","source":"Crossref","is-referenced-by-count":27,"title":["Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Victor Ho-Fun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varut","family":"Vardhanabhuti","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Cho-Lam","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Surgery, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-On","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horace Cheuk-Wai","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Wan-Hang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty Pui-Ying","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Kwok-Chuen","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Ho-Man","family":"Szeto","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Fung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See-Ching","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"To-Wai","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pek-Lan","family":"Khong","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology and Clinical Imaging Research Center, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Mau","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"},{"name":"Department of Surgery, Queen Mary Hospital, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"6","key":"zoi240534r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"zoi240534r3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi240534r4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"10","key":"zoi240534r5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/jlts.2002.34923","article-title":"Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transpl"},{"issue":"43","key":"zoi240534r6","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.3748\/wjg.v19.i43.7515","article-title":"Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.","volume":"19","author":"Pompili","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"8","key":"zoi240534r7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/lt.23892","article-title":"Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation.","volume":"20","author":"Chok","year":"2014","journal-title":"Liver Transpl"},{"issue":"1","key":"zoi240534r8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","article-title":"Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.","volume":"1","author":"Mohamed","year":"2015","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"zoi240534r9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/lt.v18.8","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.","volume":"18","author":"O\u2019Connor","year":"2012","journal-title":"Liver Transpl"},{"issue":"1","key":"zoi240534r10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000357801","article-title":"Stereotactic body radiation therapy as a bridge to transplantation and for recurrent disease in the transplanted liver of a patient with hepatocellular carcinoma.","volume":"7","author":"Mazloom","year":"2014","journal-title":"Case Rep Oncol"},{"issue":"11","key":"zoi240534r11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11547-016-0670-1","article-title":"Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma.","volume":"121","author":"Guarneri","year":"2016","journal-title":"Radiol Med"},{"issue":"1","key":"zoi240534r12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma: an intention-to-treat analysis.","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"zoi240534r13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ijrobp.2016.12.036","article-title":"Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes.","volume":"97","author":"Mannina","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi240534r14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13014-017-0899-4","article-title":"Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable hepatocellular carcinoma.","volume":"12","author":"Moore","year":"2017","journal-title":"Radiat Oncol"},{"issue":"4","key":"zoi240534r15","first-page":"261","article-title":"Stereotactic body radiotherapy used as a bridge to liver transplant in patients with hepatocellular carcinoma and Child-Pugh score =8 cirrhosis.","volume":"5","author":"Gresswell","year":"2018","journal-title":"J Radiosurg SBRT"},{"issue":"3","key":"zoi240534r16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00268-018-4829-x","article-title":"Stereotactic body radiation therapy: a new strategy for loco-regional treatment for hepatocellular carcinoma while awaiting liver transplantation.","volume":"43","author":"Uemura","year":"2019","journal-title":"World J Surg"},{"issue":"1","key":"zoi240534r17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1148\/radiol.14132362","article-title":"CT and MR imaging diagnosis and staging of hepatocellular carcinoma, part II: extracellular agents, hepatobiliary agents, and ancillary imaging features.","volume":"273","author":"Choi","year":"2014","journal-title":"Radiology"},{"issue":"1","key":"zoi240534r18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiol.14140141","article-title":"Diagnostic performance of gadoxetic acid\u2013enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan Criteria and UNOS Guidelines: correlation with histopathologic findings.","volume":"274","author":"Lee","year":"2015","journal-title":"Radiology"},{"issue":"12","key":"zoi240534r19","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1007\/s00330-019-06294-6","article-title":"The diagnostic performance of gadoxetic acid disodium\u2013enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.","volume":"29","author":"Li","year":"2019","journal-title":"Eur Radiol"},{"issue":"2","key":"zoi240534r20","first-page":"213","article-title":"11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses.","volume":"44","author":"Ho","year":"2003","journal-title":"J Nucl Med"},{"issue":"12","key":"zoi240534r21","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2967\/jnumed.108.055087","article-title":"A prospective evaluation of 18F-FDG and 11C-acetate PET\/CT for detection of primary and metastatic hepatocellular carcinoma.","volume":"49","author":"Park","year":"2008","journal-title":"J Nucl Med"},{"issue":"2","key":"zoi240534r23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"issue":"11","key":"zoi240534r24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/TP.0b013e3182a339a7","article-title":"Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.","volume":"96","author":"Chan","year":"2013","journal-title":"Transplantation"},{"key":"zoi240534r25","doi-asserted-by":"publisher","year":"2009","journal-title":"J Nucl Med","DOI":"10.2967\/jnumed.108.057307"},{"issue":"12","key":"zoi240534r27","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/sim.v33.12","article-title":"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.","volume":"33","author":"Kwak","year":"2014","journal-title":"Stat Med"},{"issue":"7","key":"zoi240534r28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial.","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi240534r29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK Consensus on normal tissue dose constraints for stereotactic radiotherapy.","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"zoi240534r30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10620-019-05538-1","article-title":"Assessing competing risks for death following liver transplantation for hepatocellular carcinoma.","volume":"64","author":"Sposito","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"1","key":"zoi240534r31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"zoi240534r2","unstructured":"Hong Kong Cancer Registry. Top ten cancers. Accessed September 30, 2023. https:\/\/www3.ha.org.hk\/cancereg\/topten.html"},{"key":"zoi240534r22","unstructured":"NRG Oncology. RTOG-1112: randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. Accessed January 7, 2015. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/rtog-1112?filter=rtog-1112"},{"key":"zoi240534r26","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. November 27, 2017. US Department of Health and Human Services. Accessed April 26, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819744\/lee_2024_oi_240534_1717182034.5978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:11:07Z","timestamp":1718032267000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819744"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15998","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}